{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T23:37:06Z","timestamp":1722987426935},"reference-count":8,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T00:00:00Z","timestamp":1288742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aim:\u2003<\/jats:bold> KW\u20102170 is a novel pyrazoloacridone derivative that intercalates nucleic acids. It has promising <jats:italic>in vitro<\/jats:italic> properties against prostate and other cancers and is active <jats:italic>in vivo<\/jats:italic> against doxorubicin\u2010resistant cell lines. We wished to investigate its activity and toxicity profile in this Phase II trial in androgen independent prostate cancer.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> Overall 44 men were recruited to this multicenter, open label, non\u2010randomized study, with 35 evaluable for prostatic specific antigen (PSA) response.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> Five patients had a PSA fall greater than 50% (overall RR 14.3%, 95% <jats:italic>CI<\/jats:italic> 4.8\u201330.3%). Overall median survival was 16\u2003months. In the evaluable group (<jats:italic>n<\/jats:italic>\u2003=\u200335), median survival was 18.9\u2003months. The drug was very well tolerated, with the most common toxicities being hematological (anemia, leucopenia, thrombocytopenia), alopecia, fatigue, and nausea. However, most of these were National Cancer Institute Grade 1 or 2; Grade 3 neutropenia occurred in only 11% of patients, and there was no Grade 4 neutropenia. Quality of life as measured by the FACT\u2013P scale was not compromised.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold> KW\u20102170 is a very well tolerated chemotherapy agent. It has a relatively low PSA response rate, and did not meet the pre\u2010specifed criteria for further studies.<\/jats:p>","DOI":"10.1111\/j.1743-7563.2010.01328.x","type":"journal-article","created":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T21:32:45Z","timestamp":1288992765000},"page":"292-297","source":"Crossref","is-referenced-by-count":4,"title":["A phase II trial of weekly i.v. KW\u20102170 in advanced castrate\u2010resistant prostate cancer"],"prefix":"10.1111","volume":"6","author":[{"given":"Paul L","family":"DE SOUZA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"NORTH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme B","family":"BOLGER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harris","family":"SPIRIDONIDIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"LIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei Siong","family":"KHOO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"PHILLIPS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"FUJIMORI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","unstructured":"KW\u20102170 Investigator's brochure. Kyowa Hakko Kogyo Co. Ltd (Japan) 4th edn December 4 2002.","DOI":"10.3833\/pdr.v2002i24.1068"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199803000-00009"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0808-z"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.12.031"},{"key":"e_1_2_6_8_2","first-page":"119a","article-title":"Pharmacokinetics and pharmacodynamics of KW 2170","volume":"21","author":"Sawyer MB","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1756"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1743-7563.2010.01328.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1743-7563.2010.01328.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:21:26Z","timestamp":1697404886000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1743-7563.2010.01328.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,3]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1743-7563.2010.01328.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1743-7563.2010.01328.x","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,3]]}}}